SCOR has published a new Focus newsletter based on the 2017 SCOR Annual Conference, “Pushing the edges of risk awareness and insurance: the role of the (re)insurance industry to cover risks affecting societies and governments”, which brought together all of the topics discussed over the past decade within a holistic framework.
The insurance industry can re-write the rules of customer engagement: tackle the distrust in sharing personal health data, address the current underwriting pain point and align with consumers’ contemporary inspirations for healthier living. As the insurance industry evolves, SCOR Global Life identified 5 new rules of consumer engagement to be front and center to address these challenges.
On February 12, the 5th SCOR Young European Researcher Prize for Research into Alzheimer’s disease was presented to Erik Portelius of Sweden’s Gothenburg University, for his findings on a new biomarker that enables earlier detection of the condition.
This new biomarker, a protein called neurogranin, paves the way for a better understanding of the disease. It allows doctors to estimate the extent of the damage to patients’ synapses and also to predict the rate of cognitive decline in patients with mild cognitive impairment. By measuring the new biomarker, the disease can be detected at an earlier stage than previously, since the loss of synapses is believed to occur early in the disease process, perhaps even earlier than neuronal loss. Until now, the degree of neuronal loss has been a difficult thing to identify in Alzheimer’s sufferers. The measurement of neurogranin, which will soon be implemented as part of a routine clinical analysis at the Clinical Neurochemistry Laboratory in Gothenburg, Sweden, involves extracting cerebrospinal fluid during a harmless lumbar puncture or spinal tap, which is then tested for the neurogranin protein.
Alzheimer’s disease is a neurodegenerative disease caused by the accumulation of proteins in the brain, permanently damaging the memory and leading to the death of the patient. There is currently no available cure. Treatments available today target the symptoms of the disease, helping patients to cope with memory loss. These treatments do not stop the progression of the disease. Nevertheless, there is reasonable hope that we will see a cure within the next 5 to 10 years. Early diagnosis of the disease will then become even more crucial in order to obtain the most effective results.
Erik Portelius accepting his award from Olivier De Ladoucette, President and Founder of the Association pour la Recherche sur Alzheimer
Extending and reinforcing a partnership initiated by SCOR in 2008, the SCOR Corporate Foundation for Science teamed up with the research program of the Alzheimer’s Research Foundation in June 2013, signing a sponsorship agreement that committed the SCOR Corporate Foundation for Science to the payment of EUR 1 million over five years. As well as creating an annual award for young European researchers, the agreement notably enables the Research Foundation to continue to observe a cohort of patients as part of a long-term study of Alzheimer’s sufferers, and to promote cooperation with foreign scientists in the field of research into this disease.